Efzofitimod Granted Orphan Drug Designation in US for Lung Disease
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to efzofitimod (ATYR1923) to treat interstitial lung disease (ILD) in people with systemic sclerosis (SSc). The therapy was developed by aTyr Pharma for treating severe diseases affecting the lungs. Efzofitimod was designated as an orphan drug…